{
  "docId": "019de072-468c-700c-89db-ca818deece7f",
  "docSlug": "40fd19b5105eee76fe8edee20250e12b",
  "documentTitle": "AN2 Therapeutics | IPO Presentation Deck | 27 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 20,
  "pageCount": 27,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a seamless trial design with specific patient counts and milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-468c-700c-89db-ca818deece7f/20",
  "deckHref": "/decks/019de072-468c-700c-89db-ca818deece7f",
  "deckJsonHref": "/decks/019de072-468c-700c-89db-ca818deece7f.json",
  "deckAnchorHref": "/decks/019de072-468c-700c-89db-ca818deece7f#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.78,
        "w": 0.68,
        "x": 0.28,
        "y": 0.03
      },
      "kind": "diagram",
      "text": "Phase 2 and Phase 3 trial design flowcharts",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3ada2ae-d047-49d9-8b45-0608ec474908",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.23,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Confirmed anticipated trial design during December 2021 FDA meeting with startup activities underway. Plan to use LPAD pathway",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f50f6af-685d-4e8c-9be4-c8d253654b02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.48,
        "x": 0.28,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "Patients who culture convert will be treated for 12 months from 1st negative culture per treatment guidelines. EOT = End-of-Therapy; LFU = Late Follow-up; LPAD = Limited population anti-infective drug pathway; OBR = Optimized Background Regimen; TBD = Final sample size to be confirmed based on Phase 2 Part data; Timelines are approx, reflect current forecast, and are subject to change.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcdae408-8f32-40b2-accd-4c7096c5293f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.18,
        "x": 0.78,
        "y": 0.82
      },
      "kind": "table",
      "text": "Milestones: 1H '22 - Start Ph 2/3 pivotal trial; Mid '23 - Ph 2 topline data; Mid '24 - Ph 3 topline data",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e66b2d5f-eff0-47de-92aa-441a284dd179",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.23,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "EBO-301: A Phase 2/3 pivotal clinical trial of epetraborole in treatment-refractory MAC lung disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "068a75e9-be98-4748-8064-b2af219ce4e4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "5949f897-b6c3-40d3-9b7f-fe33962399e2",
      "evidence": "Visual representation of clinical trial phases over time",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5c43fe0e-f0f3-4ff4-8709-c2c99c61b351",
      "evidence": "The deck starts and ends with the company's mission",
      "position": 1,
      "objective": "Present a clear mission and vision for AN2 Therapeutics",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}